Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a …

R Forman, H Deshpande, B Burtness… - Head & Neck, 2022 - Wiley Online Library
Background Paclitaxel, carboplatin, and cetuximab (PCC) has shown promise as induction
chemotherapy and in patients with metastatic/recurrent head and neck cancer (HNC). Given …
被引用次数：4 相关文章

Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a …

R Forman, H Deshpande, B Burtness… - Head & …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Paclitaxel, carboplatin, and cetuximab (PCC) has shown promise as induction
chemotherapy and in patients with metastatic/recurrent head and neck cancer (HNC). Given …

Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a …

R Forman, H Deshpande, B Burtness, AK Bhatia - Head & Neck, 2022 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Paclitaxel, carboplatin, and cetuximab (PCC) has shown promise as induction …

Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a …

R Forman, H Deshpande, B Burtness, AK Bhatia - Head & Neck, 2022 - europepmc.org
Background Paclitaxel, carboplatin, and cetuximab (PCC) has shown promise as induction
chemotherapy and in patients with metastatic/recurrent head and neck cancer (HNC). Given …